Medicare Enrolled
Dr. Wajeeha Rizvi, M.D.
Internal Medicine · Quincy, IL
Practice pattern: Mixed Practice
— Diverse clinical practice across multiple procedure types
Low-engagement
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating.
This page presents federal public records about Dr. Rizvi from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Rizvi?
Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Rizvi
Dr. Wajeeha Rizvi is an internal medicine specialist in Quincy, IL, with 10 years of NPI registration. Based on federal Medicare data, Dr. Rizvi performed 38,727 Medicare services across 1,143 unique beneficiaries.
Between the years covered by Open Payments, Dr. Rizvi received a total of $1,942 from 34 pharmaceutical and/or device companies across 82 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in internal medicine. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Rizvi is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 10 years in practice
▲ Top 1% volume in IL
$1,942 industry payments
Medicare Practice Summary
Medicare Utilization ↗38,727
Medicare services
Top 1% in IL for internal medicine
1,143
Unique beneficiaries
$11
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
~3,873 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Iron infusion (Injectafer) An intravenous injection of ferric carboxymaltose, an iron replacement medication. |
15,000 | $1 | $4 |
| Anti-nausea injection (fosaprepitant) An injection of fosaprepitant, a medication used to prevent nausea and vomiting. |
8,100 | $0 | $0 |
| Pembrolizumab injection (Keytruda) | 5,400 | $43 | $124 |
| Denosumab injection (Prolia/Xgeva) | 3,960 | $19 | $54 |
| Dexamethasone injection (steroid) An injection of dexamethasone sodium phosphate, a corticosteroid medication, administered in a dose of 1 milligram. |
1,388 | $0 | $2 |
| Anti-nausea injection (Aloxi/palonosetron) | 740 | $1 | $14 |
| Injection, leucovorin calcium, per 50 mg | 684 | $3 | $8 |
| Injection, granisetron hydrochloride, 100 mcg | 540 | $0 | $3 |
| Fluorouracil injection, 500 mg Administration of a 500 mg dose of fluorouracil medication via injection. |
385 | $2 | $11 |
| Injection, potassium chloride, per 2 meq | 295 | $0 | $2 |
| Magnesium sulfate injection, per 500 mg An injection of magnesium sulfate administered in 500 mg increments. |
273 | $1 | $3 |
| Office visit, established patient, complex (40-54 min) An office or outpatient visit for an existing patient lasting between 40 and 54 minutes. This level of service is determined by the total time spent on the date of the encounter. |
267 | $135 | $384 |
| Intravenous injection of additional new drug or substance Administration of an additional new medication or substance directly into a vein. |
213 | $11 | $77 |
| Intravenous chemotherapy infusion, 1 hour or less Administration of chemotherapy medication directly into a vein. The procedure takes one hour or less to complete. |
211 | $95 | $506 |
| Office visit, established patient (30-39 min) A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition. |
144 | $91 | $286 |
| Carboplatin chemotherapy injection, 50 mg Administration of a 50 mg dose of carboplatin, a chemotherapy medication, via injection. |
136 | $2 | $14 |
| Additional hour of intravenous chemotherapy This code represents the administration of chemotherapy medication into a vein for each additional hour beyond the initial period. |
128 | $21 | $117 |
| Additional sequential IV infusion, 1 hour or less This code represents an additional intravenous infusion administered sequentially to a primary infusion. It covers the administration time of one hour or less. |
116 | $21 | $122 |
| Intravenous infusion, 1 hour or less Administration of medication or fluid directly into a vein for therapeutic, preventive, or diagnostic purposes. The procedure lasts one hour or less. |
92 | $47 | $235 |
| Intravenous infusion of new drug or substance, 1 hour or less This procedure involves administering a new medication or substance directly into a vein through an existing access site. The infusion is completed within one hour or less. |
92 | $47 | $245 |
| Drug injection, under skin or into muscle A procedure involving the administration of a medication or substance via injection into the subcutaneous tissue or muscle. |
86 | $11 | $65 |
| Normal saline infusion, 1000 cc Administration of 1000 cc of normal saline solution into a vein. This procedure involves the intravenous delivery of a sterile saltwater solution. |
62 | $2 | $18 |
| Intravenous hydration infusion, 31-60 minutes Administration of fluids into a vein to maintain hydration. This procedure involves an infusion lasting between 31 and 60 minutes. |
60 | $24 | $183 |
| Blood sample collection from implanted device This procedure involves drawing a blood sample directly from a medical device that has been surgically placed in the body. |
51 | $19 | $109 |
| Additional hour of intravenous infusion This code represents each additional hour of intravenous infusion beyond the initial hour for therapy, prevention, or diagnosis. |
40 | $15 | $76 |
| New patient office visit (45-59 min) An initial office visit for a new patient lasting between 45 and 59 minutes. This code covers the total time spent by the physician or qualified healthcare professional on the date of the encounter. |
37 | $118 | $444 |
| IV chemotherapy initiation with community continuation Initiation of an intravenous chemotherapy infusion in a clinic using clinic supplies, with continuation of the infusion in a community setting such as home or assisted living. |
37 | $197 | $628 |
| New patient office visit, complex (60-74 min) | 36 | $155 | $550 |
| Concurrent intravenous infusion Administration of medication or fluid into a vein for therapy, prevention, or diagnosis while another infusion is being given. |
35 | $15 | $73 |
| Irrigation of implanted venous access device This procedure involves flushing an implanted venous access device to clear blockages or maintain patency. It ensures the device remains functional for delivering medications or fluids. |
25 | $19 | $92 |
| Additional hour of intravenous hydration This code represents each additional hour of intravenous fluid administration beyond the initial hour. It is used to bill for extended hydration therapy. |
24 | $10 | $58 |
| Subcutaneous or intramuscular chemotherapy injection This procedure involves administering anti-cancer hormonal medication through an injection into the tissue under the skin or into a muscle. |
24 | $24 | $109 |
| Intravenous push injection of new drug or substance A healthcare provider injects a new medication or substance directly into a vein using a push technique. |
23 | $41 | $204 |
| Unclassified drug A medication that does not fit into standard HCPCS or CPT classification categories. |
23 | $1 | $16 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
40.6% high complexity
57.9% medium
1.6% routine
Industry Payment Transparency
Open Payments through 2024 ↗$1,942
Total received (2019-2024)
Avg $388/year across 5 years
Top 22% in IL for internal medicine
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
34
Companies
82
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$1,584 (81.6%)
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$358 (18.4%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024
$847
2023
$694
2022
$157
2020
$94
2019
$150
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
Incyte Corporation
$82
AstraZeneca Pharmaceuticals LP
$76
Astellas Pharma US Inc
$73
E.R. Squibb & Sons, L.L.C.
$69
Novartis Pharmaceuticals Corporation
$53
Daiichi Sankyo Inc.
$51
GENZYME CORPORATION
$49
Janssen Biotech, Inc.
$41
Merck Sharp & Dohme LLC
$39
SOBI, INC
$32
ABBVIE INC.
$29
Regeneron Healthcare Solutions, Inc.
$28
Grifols USA, LLC
$28
Tempus AI, Inc
$25
PFIZER INC.
$23
Deciphera Pharmaceuticals Inc.
$22
Exelixis Inc.
$20
TerSera Therapeutics LLC
$20
ARRAY BIOPHARMA INC
$16
Boehringer Ingelheim Pharmaceuticals, Inc.
$15
Celgene Corporation
$15
Gilead Sciences, Inc.
$15
Rigel Pharmaceuticals, Inc.
$14
Genentech USA, Inc.
$13
Top 3 companies account for 27.3% of 2024 payments
All-time payments by company (2019-2024) ›
Novartis Pharmaceuticals Corporation
$183
Incyte Corporation
$181
AstraZeneca Pharmaceuticals LP
$171
E.R. Squibb & Sons, L.L.C.
$129
Amgen Inc.
$117
Astellas Pharma US Inc
$99
Seagen Inc.
$94
Daiichi Sankyo Inc.
$92
Merck Sharp & Dohme LLC
$73
Gilead Sciences, Inc.
$67
Celgene Corporation
$63
Janssen Biotech, Inc.
$57
Jazz Pharmaceuticals Inc.
$51
GENZYME CORPORATION
$49
Regeneron Healthcare Solutions, Inc.
$45
Exelixis Inc.
$43
Genentech USA, Inc.
$37
SOBI, INC
$32
AbbVie Inc.
$32
ARRAY BIOPHARMA INC
$31
ABBVIE INC.
$29
Grifols USA, LLC
$28
Tempus AI, Inc
$25
PFIZER INC.
$23
ADC Therapeutics America, Inc.
$23
EMD Serono, Inc.
$23
Takeda Pharmaceuticals U.S.A., Inc.
$22
Deciphera Pharmaceuticals Inc.
$22
Karyopharm Therapeutics Inc.
$20
TerSera Therapeutics LLC
$20
Mirati Therapeutics, Inc.
$17
Boehringer Ingelheim Pharmaceuticals, Inc.
$15
Eisai Inc.
$14
Rigel Pharmaceuticals, Inc.
$14
Top 3 companies account for 27.5% of all-time payments
Associated products mentioned in payments ›
ALUNBRIG · Alecensa · BAVENCIO · BRAFTOVI · CABOMETYX · CALQUENCE · Columvi · DOPTELET · ENHERTU · Enhertu · GILOTRIF · Gamunex-C · IMFINZI · INLYTA · JAKAFI · KEYTRUDA · KISQALI · KRAZATI · Kyprolis · LIBTAYO · LYNPARZA · Lenvima · MEKINIST · MONJUVI · OPDIVO · OPDUALAG · PROMACTA · Padcev · QINLOCK · REBLOZYL · RYBREVANT · Rezlidhia · SARCLISA · TASIGNA · TECVAYLI · VENCLEXTA · VYXEOS · Vyloy · XALKORI · XPOVIO · Xospata · Xtandi · Zoladex
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
Most payments (82%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians.
Geographic Context
Internal medicine physicians within 10 mi
54
Per 100K population
82.9
County median income
$64,962
Nearest hospital
BLESSING HOSPITAL
0.0 mi
0.0 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →
Summary
Dr. Rizvi is a mixed practice specialist, with above-average Medicare volume (top 1% in IL), with low-engagement industry engagement.
This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →
Frequently Asked Questions
Is Dr. Rizvi experienced with iron infusion (injectafer)?
Based on Medicare claims data, Dr. Rizvi performed 15,000 iron infusion (injectafer) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Rizvi receive payments from pharmaceutical companies?
Yes. Dr. Rizvi received a total of $1,942 from 34 companies across 82 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Rizvi's costs compare to other internal medicine physicians in Quincy?
Dr. Rizvi's average Medicare payment per service is $11. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Rizvi) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Same specialty & city
Internal Medicine Physicians in Quincy
Browse internal medicine physicians in Quincy ranked by procedure volume and transparency data.
Highest volume
Top Internal Medicine Physicians in IL
Internal medicine physicians ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Internal Medicine Physicians in IL
Which IL internal medicine physicians receive the most from drug and device companies.
By company
Novartis Pharmaceuticals Corporation Payments to Doctors
See all physicians who received payments from Novartis Pharmaceuticals Corporation.
By company
Incyte Corporation Payments to Doctors
See all physicians who received payments from Incyte Corporation.
By company
AstraZeneca Pharmaceuticals LP Payments to Doctors
See all physicians who received payments from AstraZeneca Pharmaceuticals LP.
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology